期刊文献+

基于风险分担协议的药品定价模型 被引量:1

Medicine Pricing Model Based on Risk-sharing Protocol
下载PDF
导出
摘要 从药品生产企业角度出发,以生产企业与经销企业共同利益最大化为目标,遵循市场规律,引入了风险分担协议。以药品生产企业和经销企业之间的风险分担协议为前提,通过对药品定价机制的研究,利用双层规划方法,研究了药品价格折扣的定价问题。在双层规划模型中,上层为药品生产企业最小成本模型,下层为药品经销企业最大利润期望模型。 Aiming at the maximization of the collective benefits of the manufacuturers and sales enterprises and following market disciplines, the paper introduces the risk-sharing protocol. Taking the risk-sharing protocol between the medicine manufacturing enterprises and sales enterprises as a prerequisite and through the application of bi-level programming, the paper studies the pricing and discount mechanism of medicines. The bi-level programming model consists of a upper level which is the minimal cost model of the manufacturers and a lower level which is the maximal expected profit model of the sales enterprises.
作者 温迪 林自葵
出处 《物流技术》 2010年第3期130-132,共3页 Logistics Technology
基金 国家科技支撑计划项目:药品安全追溯管理射频识别技术研究(2008BAI55B07)
关键词 药品 风险分担协议 定价 双层规划 medicine risk-sharing protocol pricing bi-level programming
  • 相关文献

参考文献5

二级参考文献17

  • 1[1]La Londe B,Ginter J.The Ohio State University 2003 Survey of Career Patterns in Logistics[EB/OL].//http://www.clm1.org.,2004.
  • 2[2]Cachon G,Fisher M.Supply Chain Inventory Management and the Value of Shared Information[J].Management Science,2000,46(3):436-443.
  • 3[3]Sahin F,Robinson E P.Flow Coordination and Information Sharing in Supply Chains:Review,Implications,and Directions for Future Research[J].Decision Sciences,2002,33(4):505-536.
  • 4[4]Wagner H M,Whitin T M.Dynamic Version of the Economic Lot-size[J].Management Science,1959,5(1):89-96.
  • 5[5]Gilbert S M,Ballou R H.Supply Chain Benefits from Advanced Customer Commitments[J].Journal of Operations Management,1999(18):61-73.
  • 6[6]LEE H L,SO K C,TANG C S.The Value of Information Sharing in a Two-level Supply Chain[J].Management Science,2000,46(5):626-643.
  • 7[7]Gavirneni S,Kapusincski R,Tayur S.Value of Information in Capacitated Supply Chains[J].Management Science,1999,45(1):16-24.
  • 8[8]CHEN F.Echelon Reorder Points,Installation Reorder Points,and the Value of Centralized Demand Information[J].Management Science,1998,44(12):221-334.
  • 9[9]Silver E A.Coordinated Replenishments of Items Under Time-Varying Demand:Dynamic Program-ming Formulation[J].Naval Research Logistics Quarterly,1979,26(1):141-151.
  • 10Dutta, S, et al. Variations in the contractual terms of cooperative advertising contracts: An empirical investigation[J].Marketing Letters, 1996,6:15 - 22.

共引文献70

同被引文献23

  • 1陈宪.我国药品定价对新药研发的影响研究[D].沈阳药科大学,2008.
  • 2韩锋.我国药品政府定价对制药企业的影响及建议[D].沈阳药科大学,2009.40-45.
  • 3《中国高技术产业统计年鉴(2012)》.
  • 4Danzon P. Making sense of drug prices E J ]. Regulation, 2000,23(1) : 56 - 63.
  • 5Vernon J. Examining the link between price regulation and pharmaceutical R~D investment [-J]. Health Economics, 2005,14(1) .- 1 - 16.
  • 6Anis AH, Wen Q. Price regulation of pharmaceuticals in Canada [-J~. Journal of Health Economics, 1998,17 (1): 21-38.
  • 7Birkett DJ, Mitchell AS, McManus P. A Cost- Effectiveness Approach to Drug Subsidy and Pricing in Australial-J~. Health affairs, 2001,20(3) : 104 - 114.
  • 8Wright DJ. The drug bargaining game: pharmaceuticals regulation in Australia. Journal of Health Economics, 2004,23(4) : 785 - 813.
  • 9Vogel RJ. Pharmaceuticals patents and price controls. Clinical Therapeutics, 2002, 24(7) : 1204 - 1222.
  • 10Thomas A, Abbott III. Price regulation in the pharmaceuticals industry: Prescription or placebo? [J] Journal of Health Economies, 1995,14(5) : 551 - 565.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部